Introduction to pralatrexate injection and interpretation of its marketing status

Pralatrexate Injection is an anti-cancer drug used to treat malignant tumors. It is an antimetabolite drug and is mainly used to treat refractory or relapsed peripheral T-cell lymphoma (PTCL). This indication has received accelerated approval based on the overall response rate. Continued approval for this indication may be contingent upon verification and characterization of clinical benefit in confirmatory trials. Pralatrexate was developed by Spectrum Pharmaceuticals. It inhibits dihydrofolate reductase (DHFR) and other enzymes related to folic acid metabolism, thereby interfering with DNA synthesis and inhibiting the proliferation of tumor cells.

Platrexate injection, as a new type of chemotherapy drug, was initially approved by the US FDA in 2011 for the treatment of peripheral T cell lymphoma (PTCL). Its efficacy is particularly significant for patients with PTCL who have failed or relapsed with traditional treatments. Pralatrexate exerts its anti-cancer effects by directly interfering with DNA synthesis. Unlike other anti-metabolite drugs, pralatrexate has good tumor selectivity and can reduce toxicity to normal cells to a certain extent.

Platrexate injection after its launch is widely used to treat relapsed or refractory peripheral T cell lymphoma. It provides a new option for many patients who cannot obtain effective treatment through traditional therapies. The use of pralatrexate is also being expanded into the treatment of other types of tumors, with studies and clinical trials currently underway around the world.

The launch of Pralatrexate Injection makes it a new option for the treatment of peripheral T cell lymphoma. However, due to the balance between its efficacy and toxic side effects, its use still needs to be cautious and under the strict supervision of doctors.

Reference materials:https://www.drugs.com/pro/pralatrexate-injection.html